Suppr超能文献

高密度脂蛋白功能作为心血管疾病的新药理学靶点:解释高密度脂蛋白对动脉粥样硬化进展保护作用的统一机制

High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis.

作者信息

Favari Elda, Thomas Michael J, Sorci-Thomas Mary G

机构信息

Department of Food and Drug, University of Parma, Parma, Italy.

Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI.

出版信息

J Cardiovasc Pharmacol. 2018 Jun;71(6):325-331. doi: 10.1097/FJC.0000000000000573.

Abstract

The formation of the atherosclerotic plaque that is characterized by the accumulation of abnormal amounts of cholesterol-loaded macrophages in the artery wall is mediated by both inflammatory events and alterations of lipid/lipoprotein metabolism. Reverse transport of cholesterol opposes the formation and development of atherosclerotic plaque by promoting high density lipoprotein (HDL)-mediated removal of cholesterol from peripheral macrophages and its delivery back to the liver for excretion into the bile. Although an inverse association between HDL plasma levels and the risk of cardiovascular disease (CVD) has been demonstrated over the years, several studies have recently shown that the antiatherogenic functions of HDL seem to be mediated by their functionality, not always associated with their plasma concentrations. Therefore, assessment of HDL function, evaluated as the capacity to promote cell cholesterol efflux, may offer a better prediction of CVD than HDL levels alone. In agreement with this idea, it has recently been shown that the assessment of serum cholesterol efflux capacity (CEC), as a metric of HDL functionality, may represent a predictor of atherosclerosis extent in humans. The purpose of this narrative review is to summarize the current evidence concerning the role of cholesterol efflux capacity that is important for evaluating CVD risk, focusing on pharmacological evidences and its relationship with inflammation. We conclude that HDL therapeutics are a promising area of investigation but strategies for identifying efficacy must move beyond the idea of simply raising static HDL-cholesterol levels and toward methods of measuring the dynamics of HDL particle remodeling and the generation of lipid-free apolipoprotein A-I (apoA-I). In this way, apoA-I, unlike mature HDL, can promote the greatest extent of cholesterol efflux relieving cellular cholesterol toxicity and the inflammation it causes.

摘要

动脉粥样硬化斑块的形成以动脉壁中异常数量的富含胆固醇的巨噬细胞积聚为特征,其由炎症事件以及脂质/脂蛋白代谢改变共同介导。胆固醇逆向转运通过促进高密度脂蛋白(HDL)介导的外周巨噬细胞胆固醇清除并将其运回肝脏以便排泄到胆汁中,从而对抗动脉粥样硬化斑块的形成和发展。尽管多年来已证实HDL血浆水平与心血管疾病(CVD)风险呈负相关,但最近的几项研究表明,HDL的抗动脉粥样硬化功能似乎由其功能介导,并不总是与其血浆浓度相关。因此,评估HDL功能(以促进细胞胆固醇流出的能力来衡量)可能比单独的HDL水平能更好地预测CVD。与此观点一致,最近有研究表明,评估血清胆固醇流出能力(CEC)作为HDL功能的指标,可能代表人类动脉粥样硬化程度的一个预测指标。本叙述性综述的目的是总结当前有关胆固醇流出能力在评估CVD风险中作用的证据,重点关注药理学证据及其与炎症的关系。我们得出结论,HDL治疗是一个有前景的研究领域,但确定疗效的策略必须超越单纯提高静态HDL胆固醇水平的理念,转向测量HDL颗粒重塑动力学和无脂载脂蛋白A-I(apoA-I)生成的方法。通过这种方式,与成熟HDL不同,apoA-I可以促进最大程度的胆固醇流出,减轻细胞胆固醇毒性及其引发的炎症。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验